Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MPI | P34949 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423446 | 1.00 | AKR1B1 (0.38) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| SCHEMBL504375 | 1.00 | AKR1B1 (0.38) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| SCHEMBL8653995 | 1.00 | AKR1B1 (0.38) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| SCHEMBL8948482 | 1.00 | AKR1B1 (0.38) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| Hydrochloric Acid SCHEMBL15779291 | 0.97 | AKR1B1 (0.36) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| Phosphoric Acid SCHEMBL5789491 | 0.91 | MPI (0.39) | AKR1B1LMNAL3MBTL1MPI | |
| SCHEMBL5699947 | 0.85 | AKR1B1 (0.43) | AKR1B1 | |
| SCHEMBL17984936 | 0.85 | HIF1A (0.41) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| SCHEMBL17984952 | 0.85 | LMNA (0.46) | AKR1B1LMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL17984927 | 0.84 | THRB (0.33) | AKR1B1HIF1AMPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0739333-B1 | SELECTIVE ASYMMETRIC HYDROGENATION OF DEHYDROAMINO ACID DERIVATIVES USING RHODIUM AND IRIDIUM DIPHOSPHINITE CARBOHYDRATE CATALYST COMPOSITIONS | DU PONT (US) | 1998-10-14 | — | — | EP | claimed |
| EP-0739333-A1 | SELECTIVE ASYMMETRIC HYDROGENATION OF DEHYDROAMINO ACID DERIVATIVES USING RHODIUM AND IRIDIUM DIPHOSPHINITE CARBOHYDRATE CATALYST COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-10-30 | — | — | EP | claimed |
| US-5510507-A | COORDINATION CATALYSTS; EFFICIENT ENANTIOSELECTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-04-23 | — | — | US | claimed |
| US-5481006-A | PREPARATION OF INTERMEDIATES FOR PHARMACEUTICALS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-01-02 | — | — | US | claimed |
| WO-1995018787-A1 | SELECTIVE ASYMMETRIC HYDROGENATION OF DEHYDROAMINO ACID DERIVATIVES USING RHODIUM AND IRIDIUM DIPHOSPHINITE CARBOHYDRATE CATALYST COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-07-13 | — | — | WO | claimed |
| US-8722864-B2 | Glycosylated acetaminophen pro-drug analogs | NuTek Pharma Ltd. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130217640-A1 | GLYCOSYLATED ACETAMINOPHEN PRO-DRUG | NuTek Pharma Ltd. | 2013-08-22 | — | — | US | disclosed |
| US-20120022012-A1 | Glycosylated Acetaminophen Pro-Drug Analogs | NuTek Pharma Ltd. | 2012-01-26 | — | — | US | disclosed |
| WO-2012012339-A2 | GLYCOSYLATED ACETAMINOPHEN PRO-DRUG ANALOGS | NuTek Pharma Ltd. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-6380168-B1 | ADMINISTERING 3-O-.BETA.-GLUCOPYRANOSYL(1-6)-.BETA.-D-GLUCOPYRANOSYL INDOLE, 2-S-.BETA.-D-GLUCOPYRANOSYL-3-O-.BETA.-D-GLUCOPYRANOSYL-2-MERC APTOINDOLE FOR INCREASING BLOOD FLOW TO SKIN | NOMURA CO., LTD. (JP) | 2002-04-30 | — | — | US | disclosed |
| US-6297363-B1 | 3-O-BETA-D-GLUCOPYRANOSYL(1-6)-BETA-D-GLUCOPYRANOSYL INDOLE; ISOLATED FROM CALANTHE DISCOLOR LINDL; FOR PROMOTION OF HAIR GROWTH AND RESTORATION | NOMURA CO., LTD. (JP) | 2001-10-02 | — | — | US | disclosed |
| EP-0739333-B1 | SELECTIVE ASYMMETRIC HYDROGENATION OF DEHYDROAMINO ACID DERIVATIVES USING RHODIUM AND IRIDIUM DIPHOSPHINITE CARBOHYDRATE CATALYST COMPOSITIONS | DU PONT (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5510470-A | CONTAINS A DIDEOXYSACCHARIDE; USED WITH ZERO VALENT NICKEL AS A CATALYST FOR ENANTIOSELECTIVE HYDROCYANATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-04-23 | — | — | US | disclosed |
| US-5484902-A | HYDROCYANATION OF VINYL AROMATICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-01-16 | — | — | US | disclosed |
| US-5481006-A | PREPARATION OF INTERMEDIATES FOR PHARMACEUTICALS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-01-02 | — | — | US | disclosed |
| US-5475146-A | Reacting vinyl compound with carbon monoxide and hydrogen in presence of catalyst containing cobalt, rhodium, platinum and/or iridium and chiral carbohydrate phosphorus ligand substituted with electron withdrawing groups | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1995018787-A1 | SELECTIVE ASYMMETRIC HYDROGENATION OF DEHYDROAMINO ACID DERIVATIVES USING RHODIUM AND IRIDIUM DIPHOSPHINITE CARBOHYDRATE CATALYST COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995006627-A1 | ENANTIOSELECTIVE HYDROFORMYLATION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-03-09 | — | — | WO | disclosed |
| US-5312957-A | 2-/6-Methoxy-2-naphthalene/propionitrile | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-05-17 | — | — | US | disclosed |
| US-5175335-A | Reacting vinyl aryl compounds with a source of hydrocyanic acid in presence of nickle zero valent compound and nonracemic bidentate organophosphorus ligand | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022012-A1 | Glycosylated Acetaminophen Pro-Drug Analogs | UGT1A3, GCG, UGT1A1 | AKR1B1 439/4885LMNA 1396/4885L3MBTL1 3901/4885 |
| US-20130217640-A1 | GLYCOSYLATED ACETAMINOPHEN PRO-DRUG | UGT1A3, GCG, UGGT1 | AKR1B1 451/4885LMNA 1464/4885L3MBTL1 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.